Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatic arterial liposomal irinotecan + 5-fluorouracil/leucovorin for second-line colorectal liver metastases
ChiCTR2600130991Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Sep 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan, fluorouracil and folinic acid in colorectal cancer liver metastasis (CRLM), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Objective response rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecanfluorouracilfolinic acid
03
Conditions
colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on ChiCTR2600130991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130991.